WATERTOWN, Mass. — January 5, 2026 — Leads & Copy — Neumora Therapeutics, Inc. (Nasdaq: NMRA) announced pipeline updates and anticipated 2026 milestones that support its mission to redefine neuroscience drug development.
The clinical-stage biopharmaceutical company expects multiple clinical data readouts in 2026, presenting an opportunity for substantial value creation. The KOASTAL-2 and -3 studies are on track for a consolidated topline readout in the second quarter of 2026. Plans are in place to conduct the NMRA-215 clinical program in 2026, following preclinical data from a diet-induced obesity model. NMRA-511 is advancing after Phase 1b results demonstrated a clinically meaningful effect on CMAI total score.
According to Neumora, cash, cash equivalents, and marketable securities are expected to support operations into the third quarter of 2027.
Paul L. Berns, co-founder, chairman, and chief executive officer of Neumora, said that 2025 was a productive and strategically important year for the company. He noted the advancement of their pipeline of novel mechanism therapies, the prioritization of obesity as the lead indication for their highly brain-penetrant NLRP3 inhibitor, NMRA-215, the expansion of their M4 PAM franchise with two new programs in clinical development, the progress of the Phase 3 program for navacaprant, and the compelling data produced for NMRA-511.
Berns added that this progress has set up important expected milestones across their programs and that they are entering a catalyst-rich period. He believes this period will meaningfully shape the future of Neumora, as well as the future of treatment for several underserved disease areas. He said that supported by a strong team, they are well-positioned to execute on their goal to advance a next generation of therapies for people living with brain diseases.
Neumora plans to increase enrollment in each of the KOASTAL studies, targeting up to 25 percent enrollment beyond the original target of 332, as the study protocols permit. The company expects a joint topline data readout for both KOASTAL-2 and KOASTAL-3 in the second quarter of 2026 and believes this approach optimizes assessment of navacaprant efficacy in major depressive disorder in the KOASTAL program.
Neumora expects to initiate a clinical program evaluating NMRA-215 monotherapy and combination therapy for the treatment of obesity in the first half of 2026. The company expects to report weight loss data following treatment with NMRA-215 around the end of 2026.
Neumora expects to provide a comprehensive M4 franchise update in mid-2026, including potentially advancing development of one or both programs.
In January 2026, NMRA-511 met the goal of the Phase 1b study, demonstrating a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable tolerability and safety profile with no reports of somnolence or sedation.
Helen Rubinstein can be reached at 617-402-5700 or Helen.Rubinstein@neumoratx.com
Source: Neumora Therapeutics, Inc.
